COMMUNIQUÉS West-GlobeNewswire

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

06/11/2024 - 23:05

Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Nov. 06, 2024 (GLOBE [...]

Appili Therapeutics Announces Results of Special Meeting of Shareholders

06/11/2024 - 23:55

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ [...]

Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction

07/11/2024 - 00:04

TUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO [...]

Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

06/11/2024 - 22:01

WESTLAKE VILLAGE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the [...]

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

06/11/2024 - 22:01

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided business highlights. " [...]

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

06/11/2024 - 22:01

LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]

Merus to Present at Upcoming Investor Conferences

06/11/2024 - 22:01

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and [...]

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

06/11/2024 - 22:01

Enrollment continues in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under development All primary and secondary endpoints met with high statistical significance in global Phase 2 CIndU study Long term 52 [...]

Outset Medical Reports Third Quarter 2024 Financial Results

06/11/2024 - 22:02

SAN JOSE, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of [...]

Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results

06/11/2024 - 22:02

SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, [...]

TerrAscend Enters Ohio with the Signing of Definitive Agreement to Acquire a Well Situated and Profitable Dispensary

06/11/2024 - 22:02

Acquisition represents the Company’s initial entry into its sixth state ; Intends to be a leader in Ohio through additional acquisitions Expected to be immediately accretive on an EBITDA and cashflow basis TORONTO, Nov [...]

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

06/11/2024 - 22:02

Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for RMC-9805, a RAS(ON) G12D- [...]

Health Catalyst Reports Third Quarter 2024 Results

06/11/2024 - 22:03

SALT LAKE CITY, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported [...]

Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific

06/11/2024 - 22:03

Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading [...]

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Troisième Trimestre 2024

06/11/2024 - 22:05

INFORMATIONS RÉGLEMENTÉES N yxoah Présente ses Résultats Financiers et d’Exploitation pour le Troisième Trimestre 2024 L'approbation de la FDA est en bonne voie pour le premier trimestre 2025, l'équipe commerciale [...]

Nyxoah Reports Third Quarter Financial and Operating Results

06/11/2024 - 22:05

REGULATED INFORMATION Nyxoah Reports Third Quarter Financial and Operating Results FDA approval on track for first quarter 2025 , U.S. commercial team build out in progress Company fully funded with cash until mid 2026 [...]

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

06/11/2024 - 22:05

ROCKVILLE, MD, November 6, 2024 — MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and [...]

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

06/11/2024 - 22:05

REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]

Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results

06/11/2024 - 22:05

Non-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted lipid nanoparticle (ctLNP) Cash balance of $199.8 million expected to fund operations into 2H 2027 CAMBRIDGE [...]